Skip to content

Six-Month Randomized, Multicenter Trial of Closed-Loop Control

One-paragraph summary

The iDCL trial randomized 168 people aged 14–71 to closed loop or sensor-augmented pump. TIR rose from 61% to 71% with closed loop and stayed 59% in controls; adjusted difference 11 percentage points (95% CI 9–14). Time below 70 mg/dL was 0.88 points lower (95% CI 0.57–1.19) (PMID 31618560).

Key findings

  • About 2.6 additional hours/day in target range.
  • Benefit persisted over six months.
  • Hyperglycemia, HbA1c, and hypoglycemia sensor metrics favored closed loop.

Limitations

  • Device-specific algorithm and supported trial environment.
  • Rare severe-event differences cannot be inferred from sensor metrics alone.

Why it matters

It established a durable outpatient AID effect using an interpretable CGM endpoint.

Cited by wiki pages

  • insulin therapy and technology
  • hypoglycemia
  • clinical trials landscape
  • overview